A proof-of-concept study of ALN-HSD for Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 21 Dec 2020
At a glance
- Drugs ALN-HSD (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
- 21 Dec 2020 New trial record
- 15 Dec 2020 According to an Alnylam Pharmaceuticals media release, the company expects to start this study in 2022.